1. Is Subcutaneous Bortezomib Ready for Prime Time?

   • Sagar Lonial

   CLINICAL TRIAL REPORT 16 February 2011 Pages: 73 - 74

2. Chronic Myelogenous Leukemia: Monitoring Response to Therapy

   • Susan Branford
   • Jodi Prime

   ReviewPaper 01 March 2011 Pages: 75 - 81

3. In Search of CML Stem Cells’ Deadly Weakness

   • Francesca Pellicano
   • Amy Sinclair
   • Tessa L. Holyoake

   ReviewPaper 04 March 2011 Pages: 82 - 87

4. Predicting the Response of CML Patients to Tyrosine Kinase Inhibitor Therapy

   • Deborah L. White
   • Timothy P. Hughes

   ReviewPaper 30 March 2011 Pages: 88 - 95

   

5. New Drugs for Chronic Myelogenous Leukemia

   • Fabio P. S. Santos
   • Alfonso Quintás-Cardama

   ReviewPaper 16 February 2011 Pages: 96 - 103

6. Treatment of Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients

   • Shaji Kumar

   ReviewPaper 11 March 2011 Pages: 104 - 112

   

7. Treatment of Newly Diagnosed Myeloma in Patients not Eligible for Transplantation

   • M. Victoria Mateos
   • Jesús San-Miguel

   ReviewPaper 24 February 2011 Pages: 113 - 119

8. New Immunomodulatory Drugs in Myeloma

   • Martha Q. Lacy

   ReviewPaper 16 February 2011 Pages: 120 - 125

9. Updates in Cytogenetics and Molecular Markers in MDS

   • Ramon V. Tiu
   • Valeria Visconte
   • Jaroslaw P. Maciejewski

   ReviewPaper 22 February 2011 Pages: 126 - 135

10. The Relevance of Iron Overload and the Appropriateness of Iron Chelation Therapy for Patients with Myelodysplastic Syndromes: A Dialogue and Debate

    • David P. Steensma

    ReviewPaper 05 March 2011 Pages: 136 - 144

    

11. Management of Lower-Risk Myelodysplastic Syndromes:The Art and Evidence

    • Rami S. Komrokji
    • Mikkael A. Sekeres
    • Alan F. List

    ReviewPaper 26 March 2011 Pages: 145 - 153